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ABSTRACT
Melicope ptelefolia is a medicinal plant from the Rutaceae, also known as ‘tenggek burung’ in Malaysia. Traditionally, 
natives ingest M. ptelefolia to treat a wide range of illnesses. This study aimed to investigate the effects of M. ptelefolia 
aqueous extract (MPAE) on compound action potentials (CAPs) in frog sciatic nerves and its mechanism involving the 
opioid receptors. The effects of MPAE on CAPs in frog sciatic nerves were examined using the AD Instrument Nerve 
Chamber. The frog sciatic nerves were dissected from the lumbar plexus to the knee of the frog and placed in Ringer’s 
solution. Three treatment groups with different dosages (1, 3 and 10 mg/mL) of MPAE, including negative (vehicle) and 
positive control group (3 mg/mL of morphine) were tested on the frog sciatic nerves by placing them in a nerve organ 
chamber. Following this, the involvement of opioid receptors in the effects of MPAE on CAPs was investigated by using 
naloxone hydrochloride as a non-selective opioid receptor antagonist. Our results showed that the peak amplitudes of 
CAPs were significantly (p<0.001) reduced when treated with MPAE (3 and 10 mg/mL) in frog sciatic nerves. The MPAE-
induced CAPs inhibition was reversed when pre-treated with naloxone, suggesting the involvement of the opioidergic 
system. These results indicated the modulatory action of MPAE on nerve conduction, which may provide important leads 
in the development of new therapeutic drugs through the involvement of opioid receptors.
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ABSTRAK
Melicope ptelefolia adalah sejenis tumbuhan ubatan daripada Rutaceae, juga dikenali sebagai ‘tenggek burung’ di 
Malaysia. Secara tradisinya, penduduk pribumi menggunakan M. ptelefolia untuk merawat pelbagai jenis penyakit. 
Kajian ini bertujuan untuk mengkaji kesan ekstrak akuas M. ptelefolia (MPAE) terhadap potensi tindakan sebatian 
(CAPs) dalam saraf skiatik katak dan mekanisme yang melibatkan reseptor opioid. Kesan MPAE pada CAPs saraf skiatik 
dikaji menggunakan AD Instrument Nerve Chamber. Saraf skiatik katak dibedah dari pleksus lumbar ke lutut katak dan 
diletakkan di dalam larutan Ringer. Sebanyak tiga kumpulan rawatan dengan dos yang berbeza (1, 3 dan 10 mg/mL) 
MPAE, dengan kumpulan kawalan negatif (pembawa) dan positif (3 mg/mL morfin) diuji pada saraf skiatik katak dengan 
meletakkannya dalam ruang organ saraf. Berikutan itu, penglibatan reseptor opioid dalam mekanisme MPAE menghalang 
CAP telah dikaji dengan menggunakan nalokson hidroklorida sebagai antagonis reseptor opioid yang tidak memilih. 
Hasil kajian kami menunjukkan bahawa puncak amplitud potensi tindakan sebatian telah berkurang dengan ketara 
(p<0.001) apabila dirawat dengan ekstrak akua M. ptelefolia (3 dan 10 mg/mL) dalam saraf skiatik katak. Perencatan 
CAPs yang disebabkan oleh MPAE dibalikkan apabila saraf skiatik menerima pra-rawatan dengan nalokson mencadangkan 
penglibatan sistem opioidergik. Hasil kajian ini menunjukkan tindakan modulasi MPAE pada pengaliran saraf yang dapat 
memberikan petunjuk yang penting dalam perkembangan dadah terapeutik baru melalui penglibatan reseptor opioid.
Kata kunci: Melicope ptelefolia; opioidergik; potensi tindakan sebatian; reseptor opioid; saraf skiatik katak
INTRODUCTION
Excitation of nerve cells results in a momentary change in 
membrane potential, resulting in the propagation of nerve 
signals. This interaction between extracellular substance 
and intracellular medium is known as action potential 
(Bogatov et al. 2014). Compound action potential (CAP) 
is the combined propagation of nerve signals of a group 
of fibres of cell. Peripheral nerves produce CAPs in both 
proximal and distal sites in the presence of a stimulus. 
Measurements such as action potential amplitudes and 
conduction velocity in different nerve segments can be 
graphically analyzed from CAPs (Li 2015).
 As modern medicine may manifest many undesirable 
side effects, more research on natural product is required. 
1620 
One of the natural products is Melicope ptelefolia which 
is a medicinal plant from the Rutaceae family, known as 
‘tenggek burung’, ‘pauh-pauh’ and also ‘cabang tiga’ in 
Malaysia. This plant is claimed by the natives to treat fever, 
pain, wounds and itches (Karim et al. 2011). Previous 
studies have stated that M. ptelefolia leaf extract has anti-
inflammatory, analgesic and antinociceptive properties 
(Sulaiman et al. 2010). Inhibition of nerve conduction is 
one of the mechanisms on pain modulation. Therefore, 
M. ptelefolia may give inhibitory effect on CAPs as it has 
already shown antinociceptive properties. 
 In this study, naloxone hydrochloride was used as a 
non-selective opioid receptor antagonist to determine the 
involvement of opioid receptors in the effects of MPAE. 
The opioid receptor subtypes namely Mu (μ), Delta (δ), 
and Kappa (κ), are often targeted for pain treatments (Al-
Hasani & Bruchas 2011). Activation of opioid receptors 
typically inhibits transmission of action potentials. Thus, 
usage of an opioid receptor antagonist often provides 
preliminary results on whether a compound acts through 
opioid receptors. Excited neuronal transmission of 
action potentials will occur at a constant rate if a certain 
compound elicits its effects without involvement of opioid 
receptors. 
 However, to the best of our knowledge, there is still 
no report examining the actions of Melicope ptelefolia 
aqueous extract (MPAE) on nerve conduction. Therefore, 
this study aimed to investigate the effects of MPAE on 
CAPs in frog sciatic nerves and its mechanism involving 
the opioidergic system. The results of this study will 
highlight the underlying activity of M. ptelefolia extract 
as an analgesic emphasising the use of natural products 
for clinical practice.
MATERIALS AND METHODS
PLANT EXTRACTION
Fresh leaves of M. ptelefolia were bought from Pasar 
Borong, Serdang, Selangor, Malaysia. The fresh leaves 
were identified and authenticated by a resident botanist 
through comparison with herbarium specimens of M. 
ptelefolia (SK 3071/16) kept at the Mini Herbarium, 
Institute of Bioscience, Universiti Putra Malaysia (UPM). 
The aerial parts of the plants, including the stems and 
leaves were washed and oven-dried for 48 h at 40°C. 
Dried leaves were ground and stored at -20°C. The 
powdered leaves were heated at about 80°C with an 
extraction ratio of approximately 1:10 of distilled water. 
The MPAE was freeze-dried for 3 days and stored at 4°C 
until further use.
EXPERIMENTAL ANIMALS
Rana catesbeiana frogs of either sex, weighing 200 to 
300 g, were used in this experiment. All the experiments 
were conducted in accordance with the ethical guidelines 
on animal experimentation. The protocols and procedures 
were approved by the Institutional Animal Care and Use 
Committee (IACUC) of Universiti Putra Malaysia (Ref: 
UPM/IACUC/AUP-U001/2017). All efforts were made to 
minimise animal suffering and the number of animals used.
DRUG PREPARATION
M. ptelefolia aqueous extract (MPAE) (1, 3 and 10 mg/mL) 
was used as treatment in this experiment. Vehicle group 
received a mixture of 95% normal saline and 5% Tween 
20. Morphine (3 mg/mL, 10 mM) was used as the positive 
control. Naloxone hydrochloride (0.1 mg/mL, 0.27 mM), a 
non-selective opioid receptor antagonist, was used to study 
the involvement of opioidergic system. Ringer’s solution 
(NaCl, 115.5 mM; KCl, 2.0 mM; CaCl2, 1.8 mM; Na2HPO4, 
1.3 mM; and NaH2PO4, 0.7 mM (pH = 7.0)) was used as 
temporary medium to keep the sciatic nerves before CAPs 
measurement procedures.
EXPERIMENTAL DESIGN
For the first set of experiment, the effects of MPAE on CAPs 
were evaluated whereas the involvement of the opioidergic 
pathway was investigated as the second set of experiment. 
The experimental timeline and treatment groups are as 
shown in Figure 1 and Table 1, respectively.
PREPARATION OF FROG SCIATIC NERVES
The method used for isolation and preparation of frog 
sciatic nerves was as previously described (Katsuki et 
al. 2006; Kosugi et al. 2010; Mizuta et al. 2008). Frogs 
were decapitated and then pithed; the sciatic nerves were 
dissected from the lumbar plexus to the knee. Throughout 
dissections, Ringer’s solution was continuously applied 
to the nerves to keep it moist. Sciatic nerves were kept in 
Ringer’s solution before measuring the CAPs.
RECORDINGS OF CAPS FROM FROG SCIATIC NERVE
CAPs were recorded using AD Instrument Nerve Chamber 
and LabTutor Software. The frog sciatic nerve was placed 
at the center of the chamber and the nerve was stimulated 
for recording of CAPs. The stimulation was started at 10 
mV and measurements were recorded when the voltage 
reached 200 mV. CAPs were recorded before and after 
exposure to their respective experimental group treatments. 
The relative peak amplitude of CAPs was measured as the 
difference between baseline and CAPs peak levels (Yao et 
al. 2015). All procedures were performed quickly to avoid 
losing moisture of the sciatic nerve.
EFFECTS OF MPAE ON CAPs
The effects of MPAE were determined by using 5 
experimental groups, which were the negative control 
(vehicle), MPAE treatment (1, 3 and 10 mg/mL) and 
positive control (morphine, 3 mg/mL). The CAPs of 
frog sciatic nerves were recorded before each treatment 
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procedure. Sciatic nerves were soaked with respective 
treatments according to their experimental groups for 
30 min.
INVOLVEMENT OF OPIOIDERGIC SYSTEM
The involvement of opioidergic system was investigated 
using four experimental groups which were negative 
control (vehicle), MPAE treatment (3 mg/mL), naloxone 
hydrochloride (0.1 mg/mL) and MPAE (3 mg/mL) with 
naloxone hydrochloride group. Sciatic nerves (n=6) were 
pre-treated with naloxone hydrochloride (0.1 mg/mL) for 
20 min prior to soaking in MPAE (3 mg/mL) for 30 min.
DATA ANALYSIS
Data are presented in relative CAPs amplitude with 
mean ± S.E.M. and analysed using two-way ANOVA 
followed by Bonferonni’s post-hoc test. The values were 
analysed using GraphPad Prism v5.0 software (GraphPad 
San Diego, CA) and the statistical significance was set at 
p< 0.05.
RESULTS
Effects of treatments on CAPs were examined in a total 
of 54 sciatic nerves with average peak amplitudes of the 
TABLE 1. Experimental treatment groups for sciatic nerves (n=6) 
collected from a total of 27 animals
Experiment 1: Inhibitory effects of MPAE on CAPS
Vehicle -
M. ptelefolia aqueous extract (MPAE)
1 mg/mL
3 mg/mL
10 mg/mL
Morphine 3 mg/mL
Experiment 2: Involvement of opioidergic pathway
Vehicle
MPAE
Naloxone hydrochloride
MPAE + Naloxone hydrochloride
-
3 mg/mL
0.1 mg/mL
3 + 0.1 mg/mL
A
B
FIGURE 1. (A) Experiment 1: Investigating the inhibitory effects of MPAE on CAPs and (B) Experiment 2: 
Investigating the involvement of the opioidergic system in the inhibitory effects of MPAE
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CAPs of 25.0±1.6 mV. Complete recovery of CAPs peak 
amplitude was achieved after washing out the sciatic 
nerves for 30 min.
EFFECTS OF Melicope ptelefolia AQUEOUS EXTRACT                    
IN FROG SCIATIC NERVES CAPS
The effects of MPAE on frog sciatic nerves were examined 
by soaking the nerves in three different dosages, which 
were 1, 3 and 10 mg/mL. Inhibitory effects of the three 
dosages of MPAE as shown in Figure 2, were compared 
with controls. Reduction in CAPs peak amplitude was 
dose-dependent when treated with MPAE at 1, 3 and 10 
mg/mL, where 3 and 10 mg/mL showed almost similar 
inhibition to CAPs peak amplitude. MPAE effects at 3 mg/
mL (14.2±1.4 mV; n=6) and 10 mg/mL (11.9±0.9 mV; n=6) 
were both significantly different (p<0.001) after treatment 
when compared to vehicle (21.0±2.2 mV; n=6).
 In order to compare the effects of MPAE with other 
established analgesics, we investigated the effects of 
morphine (3 mg/mL) on CAPs peak amplitudes. Following 
exposure of sciatic nerves to morphine, CAPs amplitude 
significantly reduced (12.3±0.7 mV; n=6, P < 0.001) 
as shown in Figure 2. The reduction of CAPs amplitude 
30 min after exposure of respective treatments was not 
significantly different between MPAE (3 and 10 mg/mL) 
and morphine (3 mg/mL) where the CAPs amplitudes 
were 14.2±1.4 mV, 11.9±0.9 mV and 12.3±0.7 mV, 
respectively.  
 Traces of the nerves soaked in 3 mg/mL of MPAE 
reducing the CAPs amplitude were compared to control 
(vehicle) as shown in Figure 3 demonstrates the relative 
CAPs amplitudes of MPAE (3 mg/mL) with maximal 
reduction effects were observed after 30 min of treatment 
(Figure 4). After the washing process, CAPs increased and 
returned to normal as the control after 60 min.
EFFECT OF OPIOID RECEPTOR ANTAGONIST                               
IN FROG SCIATIC NERVES CAPs
Naloxone hydrochloride, a non-specific opioid receptor 
antagonist, was used to determine the involvement of 
the opioidergic system in the MPAE-induced reduction of 
CAPs amplitude. Traces between the control, naloxone 
and naloxone with MPAE were compared between groups 
(Figure 5). Pre-treatment with naloxone alone did not 
significantly affect the CAPs. As shown in Figure 6, the 
reversible inhibition of MPAE at 3 mg/mL occurred in 
the presence of an opioid receptor antagonist. Following 
exposure to naloxone (0.1 mg/mL) for 20 min with MPAE 
treatment (21.9±1.5 mV; n=6), the CAPs amplitude was 
significantly different from results obtained by treatment 
of MPAE alone (14.2±1.4 mV; n=6, p<0.001).
FIGURE 3. Comparison of CAPs amplitude curves between control and MPAE (3 mg/mL) 
treatment 30 min after soaking. The MPAE curve obtained at 30 min has lower peak amplitude 
compared to the control, with the peak returning to normal after 30 min of washing
FIGURE 2. Changes in relative CAPs amplitudes of sciatic nerves in control, Melicope ptelefolia 
aqueous extract (MPAE) at 1, 3 and 10 mg/mL and morphine treated groups 30 min following 
soaking. Each point represented CAPs peak amplitude following exposure to respective 
treatment, relative to values obtained prior to soaking, in six sciatic nerves
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FIGURE 4. Average time course changes in CAPs peak amplitudes from sciatic nerves soaked in MPAE (3 mg/
mL) over a period of 60 min. After the washing process, the relative CAP amplitudes returned to normal at 
60 min. Each point represented CAPs peak amplitude following exposure to MPAE (3 mg/mL) and washing, 
relative to values obtained prior to soaking, in six sciatic nerves
FIGURE 5. Comparison of CAPs amplitude curves between control, naloxone hydrochloride and 
naloxone hydrochloride pre-treated prior to MPAE (3 mg/mL) 30 min after soaking. Exposure of the 
sciatic nerves to naloxone hydrochloride, a non-selective opioid receptor antagonist, prevented the 
inhibitory effects of MPAE on CAPs peak amplitude
FIGURE 6. Average time course changes in CAPs peak amplitudes from sciatic nerves pre-treated with naloxone hydrochloride, a 
non-selective opioid receptor antagonist, prior to soaking with MPAE (3 mg/kg) over a period of 60 min. Exposure to naloxone 20 
min prior to treatment reverses the inhibitory effect of MPAE to CAPs peak amplitude. Each point represented CAPs peak amplitude 
following exposure to naloxone and MPAE (3 mg/mL), relative to values obtained prior to soaking, in six sciatic nerves
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DISCUSSION
This study was carried out to investigate the effects of MPAE 
on CAPs in frog sciatic nerves, tested with three different 
dosages. To ensure absence of error or bias in recording 
of CAPs amplitudes, the setup was tested daily before 
recording by placing the filter paper soaked with Ringer’s 
solution. The M. ptelefolia aqueous extract (MPAE) was 
dissolved in 95% of normal saline and 5% of Tween 20. The 
sciatic nerves treated with vehicle were recorded and acted 
as the negative control to ensure the inhibition of CAPs 
during MPAE treatment was caused by the extract itself.
 This study was the first to show the effects of MPAE on 
nerve conduction through inhibition on CAPs amplitudes, 
which was dose-dependent in the range of 1 to 10 mg/mL. 
Based on the results, CAPs gradually decreased across the 
period of soaking in all three dosages of MPAE. The sciatic 
nerves soaked in 10 mg/mL of MPAE gave the maximal 
inhibition on CAPs at 30 min with 50% inhibition whereas 
MPAE at 3 mg/mL had almost 50% inhibition on CAPs. 
Morphine (3 mg/mL) was significantly different when 
compared to vehicle, where a 40% reduction of CAPs was 
observed (p<0.001). As the effects of 3 mg/mL of MPAE on 
CAPs were as strong as 10 mg/mL, therefore 3 mg/mL of 
MPAE was chosen as the optimum dose for Experiment 2.
 The effect of MPAE inhibition on CAPs could occur 
through nonspecific membrane bilayer interactions or 
through inhibition of tetraethylammonium(TEA)-sensitive 
K+ channels and/or tetrodotoxin(TTX)-sensitive voltage-
gated Na+ channels (Mizuta et al. 2008). The intensity of 
CAPs amplitude relies on the influx of Na+, efflux of K+ and 
the resting potential level. The involvement of these ion 
channels could be observed from the CAPs graph whereby 
the rise period of action potential represents Na+-dependent 
parameters and repolarisation period represents K+ efflux-
dependent parameters (Pandey & Deshpande 2012). 
Further studies on how MPAE interacts with Na+ and K+ 
channels should be conducted. 
 Our results showed that the effects of MPAE on sciatic 
nerves CAPs were inhibited when pre-treated with naloxone 
(0.1 mg/mL). As there was no significant difference in CAPs 
amplitudes across the time (0-50 min), opioid receptors 
may be involved in the inhibitory effects of MPAE on nerve 
conduction. A study by Uemura et al. (2014) showed that 
analgesics exert their antinociceptive effects through 
inhibition of nerve action potential conduction. Previous 
study on the M. ptelefolia extract in an animal model of 
antinociception exhibited analgesic properties (Sulaiman 
et al. 2010). The ability of MPAE to reduce CAPs amplitude 
is therefore correlated with inhibition of nerve conduction, 
which indirectly alleviates pain (Sandkühler 2000). The 
opioidergic system is one of the highly important pain 
modulatory systems in the pain pathway and the effects of 
MPAE on CAPs amplitude may have been mediated by opioid 
receptors. Previous studies on opioids showed reduction 
on CAPs amplitudes due to the presence of opioid receptors 
on nerve fibres (Fields et al. 1980; Gissen et al. 1987; 
Jaffe & Rowe 1996). The inhibitory effect of morphine 
is highly sensitive to the presence of naloxone, which 
antagonised the CAPs amplitude reduction, demonstrating 
the involvement of opioid receptors (Jurna & Grossman 
1977).
 There are various pathways and receptors that may 
cause an effect towards CAPs. In this paper, we showed 
that MPAE activity on nerve conduction was influenced 
by opioid receptors. Exogenous opioids for example, 
do not exert its inhibitory effects solely through opioid 
receptors. Güven et al. (2005) reported that tramadol, a 
centrally acting opioid, has low affinity to opioid receptors. 
Instead, tramadol inhibits peripheral nerve conduction via 
blockade of Na+ and K+ channels. Thus, it is possible that 
other receptors and channels influence MPAE-induced CAPs 
inhibition. 
CONCLUSION
In summary, the present study showed that M. ptelefolia 
aqueous extract (MPAE) has the ability to modulate nerve 
conduction by inhibiting CAPs. Inhibitory mechanism, 
particularly through the involvement of the opioidergic 
system was demonstrated with 3 mg/mL of MPAE. Our 
findings indicated that MPAE has high potential as a 
naturally sourced analgesic where it could serve in both 
nutraceutical and drug industries.
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